SCHEMBL1474935

SCHEMBL1474935

O=C(NCCc1ccncc1)c1cc(-c2ccccc2)on1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.81
MAPT P10636 3/20 0.69
POLB P06746 1/20 0.65
HIF1A Q16665 3/20 0.65
RAB9A P51151 5/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
NPC1 O15118 3/20 0.63
ALDH1A1 P00352 2/20 0.63
LMNA P02545 3/20 0.62
HPGD P15428 1/20 0.62
HSD17B10 Q99714 1/20 0.62
KMT2A Q03164 2/20 0.62
HTT P42858 1/20 0.59
MAPK1 P28482 1/20 0.59
HDAC3 O15379 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16486106 0.92 FAAH (0.95) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1475159 0.89 FAAH (0.68) FAAHMAPTRAB9ANPC1ALDH1A1
SCHEMBL1474945 0.88 MAPT (0.64) FAAHMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL1474540 0.88 FAAH (0.67) FAAHMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL1475769 0.88 HDAC6 (0.68) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1475365 0.88 FAAH (0.81) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1474724 0.87 MAPT (0.63) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1476073 0.87 MAPT (0.63) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1475308 0.87 RAB9A (0.79) FAAHMAPTPOLBHIF1ARAB9A
SCHEMBL1476942 0.86 FAAH (0.80) FAAHMAPTPOLBHIF1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 FAAH 4712/4885MAPT 2497/4885POLB 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.